Viking Therapeutics Q4 net loss widens, hurt by higher R&D expenses

Viking Therapeutics

11/02/2026 21:25

Overview

Biopharmaceutical firm's Q4 loss per share and net loss missed analyst expectations

Company reported a Q4 net loss of $157.7 mln, primarily due to increased R&D expenses

Company maintained "strong" cash position of $706 mln at year-end

Outlook

Viking plans Phase 3 trials for oral VK2735 in 3Q26

Company expects VK2735 maintenance dosing study results in 3Q26

Viking to file IND for novel amylin agonist this quarter

Result Drivers

HIGHER RESEARCH AND DEVELOPMENT EXPENSES: Research and development expenses were $153.5 million for the three months ended December 31, 2025, compared to $31.0 million for the same period in 2024.

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 EPS
Miss
-$1.38
-$0.89 (17 Analysts)
Q4 Net Income
Miss
-$157.66 mln
-$101.59 mln (15 Analysts)
Q4 Income from Operations
Miss
-$164.74 mln
-$107.13 mln (15 Analysts)
Q4 Operating Expenses
$164.74 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 17 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Viking Therapeutics Inc is $101.50, about 253% above its February 10 closing price of $28.75

Press Release: ID:nPnbHFZ3ha

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)